



HAL
open science

Clinical implications of CTNNA1 germline mutations in asymptomatic carriers

Patrick R Benusiglio, Chrystelle Colas, Erell Guillerm, Axelle Canard, H el ene Delhomelle, Mathilde Warcoin, J er ome Bellanger, M elanie Eyries, Mohamed Zizi, Jeanne Netter, et al.

► **To cite this version:**

Patrick R Benusiglio, Chrystelle Colas, Erell Guillerm, Axelle Canard, H el ene Delhomelle, et al.. Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. *Gastric Cancer*, 2019, 22 (4), pp.899-903. 10.1007/s10120-018-00907-7 . hal-02361765

HAL Id: hal-02361765

<https://hal.sorbonne-universite.fr/hal-02361765v1>

Submitted on 13 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.

Short communication: Clinical implications of *CTNNA1* germline mutations in asymptomatic carriers

Patrick R. Benusiglio ^{1,2*}, Chrystelle Colas ^{1,2,3*}, Erell Guillerm ⁴, Axelle Canard ⁵, H el ene Delhomelle ², Mathilde Warcoin ¹, J er ome Bellanger ^{2,6}, M elanie Eyries ⁴, Mohamed Zizi ⁴, Jeanne Netter ², Florent Soubrier ^{4,7}, Yann Parc ^{2,7}, Anne Mourregot ⁸, Aur elie Maran Gonzalez ⁹, Veronica Cusin ^{1,10}, J er ome A. Denis ^{4,7,11}, Isabelle Coupier ¹², Magali Svrcek ^{5,7}, Florence Coulet ^{4,7}.

1. Consultation d'Oncog en tique, Unit  fonctionnelle d'Oncog en tique, D epartement de G en tique, Groupe Hospitalier Piti -Salp tri re AP-HP, F-75013 Paris, France.

2. Service de Chirurgie g en rale et digestive, H opital Saint-Antoine AP-HP, F-75012 Paris, France.

3. Service de G en tique, Institut Curie, F-75005 Paris, France.

4. Laboratoire d'Oncog en tique, Unit  fonctionnelle d'Oncog en tique, D epartement de G en tique, Groupe Hospitalier Piti -Salp tri re AP-HP, F-75013 Paris, France.

5. Service d'Anatomie et Cytologie pathologiques, H opital Saint-Antoine AP-HP, F-75012 Paris, France.

6. Service de Gastro-ent rologie et Nutrition, H opital Saint-Antoine AP-HP, F-75012 Paris, France.

7. Sorbonne Universit , Facult  de M edecine, F-75013 Paris, France.

8. D epartement de Chirurgie Oncologique, Institut du Cancer de Montpellier (ICM), Montpellier, France.

9. Service d'Anatomie Pathologique, Institut du Cancer de Montpellier (ICM), Montpellier, France.

10. Institut de Canc rologie, H opital Priv  des Peupliers, Paris, France.

11. Service de Biochimie endocrinienne et oncologique, Groupe Hospitalier Piti -Salp tri re AP-HP, F-75013 Paris, France.

12. Unit  d'Oncog en tique, Service de G en tique, CHU de Montpellier, France.

*PRB and CC contributed equally to this work.

Corresponding author

PR Benusiglio, patrick.benusiglio@aphp.fr, patrick.benusiglio@cantab.net. +33 1 42 17 76 59.

Running title: *CTNNA1* mutations in healthy carriers

Keywords: Diffuse gastric cancer, *CDH1*, *CTNNA1*, signet ring cell, hereditary cancer.

Word count: 1648

Manuscript published in Gastric Cancer(July 2019, Volume 22, Issue 4, pp 899–903; online 4 December 2018) : <https://link.springer.com/article/10.1007%2Fs10120-018-00907-7>

Abstract

In 2017, we implemented *CTNNA1* germline analysis in probands suspected of having hereditary diffuse gastric cancer. Here, we report the results from a retrospective series of 41 cases, including the identification of a new family with a *CTNNA1* mutation and the first prophylactic total gastrectomy in an asymptomatic carrier after a normal upper endoscopy. Diffuse gastric cancer foci with loss of catenin alpha-1 expression were seen in the resected tissue, suggesting that *CTNNA1* and *CDH1* germline mutations behave in a similar manner. Life-changing prophylactic total gastrectomy should therefore also be considered in *CTNNA1* mutation carriers.

Mini-abstract

Prophylactic total gastrectomy should be considered in asymptomatic carriers of *CTNNA1* germline mutations, as recommended for *CDH1* mutation carriers.

Introduction

Diffuse gastric cancer (DGC) is a gastric cancer subtype characterized by signet-ring cells infiltrating the mucosa and wall as small clusters or scattered individual cells. Germline mutations in cancer susceptibility genes account for a minority of cases, and carriers of such mutations are said to have hereditary DGC (HDGC).

The consensus HDGC testing criteria, which were revised in 2015, are based on family history and age at diagnosis (e.g. two DGC cases in a family, sporadic DGC < age 40), and raise the possibility of genetic susceptibility. When these criteria are fulfilled, genetic testing is recommended [1], [2]. Until recently, *CDH1* was the only known susceptibility gene, with a germline pathogenic variant present in 14%-20% of probands meeting the HDGC testing criteria [3]–[5]. *CDH1* codes for the E-cadherin adhesion protein. Testing of probands is beneficial, as the identification of a mutation leads to cascade testing within the family and risk-reducing measures in asymptomatic carriers. The vast majority of *CDH1* mutation carriers have malignant or premalignant foci in their stomachs that

commonly evade detection by upper endoscopy [6], [7]. There is therefore no effective screening approach, and the only consensus recommendation in asymptomatic carriers is prophylactic total gastrectomy (PTG).

In the past five years, truncating germline variants in *CTNNA1* (*catenin alpha-1*), which encodes a *CDH1*-binding partner, have been identified in five families with multiples DGC cases [3], [8], [9]. *CTNNA1* is therefore another DGC susceptibility gene, albeit rarely involved, since 320 probands had to be investigated in order to identify these families. Given the recent identification of *CTNNA1*, data regarding the benefit of presymptomatic testing and the subsequent management of asymptomatic carriers are lacking. To adequately inform and guide families, this gap in knowledge needs to be filled.

Following earlier reports of the association between *CTNNA1* mutations and HDGC [3], [8], we implemented *CTNNA1* germline analysis in all probands with suspected HDGC. We report herein a retrospective series of 41 probands, including the identification of a new family with a *CTNNA1* mutation and the first prophylactic total gastrectomy in an asymptomatic carrier after a normal upper endoscopy.

Material and Methods

Patient selection

Since 01 January 2017, *CTNNA1* has been included in our “genetic susceptibility to digestive cancer” NGS panel. Sanger sequencing was implemented simultaneously for retrospective patients. This work reports *CTNNA1* results in a retrospective series of *CDH1*-negative probands with suspected HDGC. Cases were selected for analysis because they fulfilled the 2015 testing criteria, or had a personal/family history that was close to these criteria, mainly sporadic DGC between the ages of 40 and 50. They came from two Paris University Hospitals affiliated with the laboratory (La Pitié-

Salpêtrière, Saint-Antoine), and from partner cancer genetics clinics located throughout France. All signed an informed consent form.

Gene sequencing

Sequencing was performed at the Pitié-Salpêtrière Cancer Genetics Laboratory. The sequence analysis of the coding exons and exon/intron boundaries of the *CTNNA1* gene (NM_001903.3) was performed on genomic DNA extracted from peripheral lymphocytes for all selected patients. The purified PCR products were sequenced in both directions using the BigDye Terminator v3.1 chemistry (ThermoFisher Scientific). Sequencing reactions were run on an ABI3730 DNA Analyzer and analysed with the SeqScape software v2.6. All primer sequences and amplification conditions are available on request.

Immunohistochemistry

Catenin alpha-1 protein expression was studied by immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded material. Briefly, IHC staining was performed on one representative tumor block from each case. Sections of 4 µm were incubated with a mouse monoclonal antibody against α-E-catenin for 20 minutes (clone EP1793Y, Abcam, dilution 1/200). Staining was performed with a Leica immunohistochemistry automate. Catenin alpha 1 was detectable in normal epithelial structures (e.g the glands of the stomach). Staining was scored according to the percentage of positive tumor cells.

Results

Thirty-two out of 41 probands met the 2015 HDGC testing criteria. A truncating germline variant, *CTNNA1* c.2023C>T, p.Gln675*, was identified in a female with a DGC history at age 58 (III.1, Fig.1). She died of the disease in 2008. Four first-degree relatives had a history of gastric cancer at the ages of 39, 40 (n=2) and 52, two of them were confirmed as having DGC (III.3 and III.5). One sister with GC also had ductal breast cancer at age 44. None of the affected relatives was alive. As we had access to tumor tissue for individual III.3, we performed a co-segregation analysis and found the *CTNNA1*

variant (Fig. 1). Individual III.2, with no history of cancer, did not carry it. In the proband and individual III.3, catenin alpha-1 expression was lost in 90% and 100% of the DGC tumor cells, respectively.

The *CTNNA1* c.2023C>T, p.Gln675* truncating variant is not reported in the gnomAD database of germline mutations. It is reported once in the TCGA database of somatic mutations, but in a bladder cancer. Given the pathogenic nature of the variant, we then carried out presymptomatic testing in eight adult relatives. Two females aged 32 and 20 were mutation carriers (IV.8 and IV.10, respectively). Screening esophagogastroduodenoscopy (EGD) using white light, narrow band imaging, and coloration with indigo carmine was visually normal in patient IV.10, and no DGC foci were observed in 16 random biopsies. Following multidisciplinary assessment, and considering the *CTNNA1* germline mutation and the strong family history of DGC, she underwent PTG. The entire stomach was processed into paraffin blocks. All were stained with haematoxylin and eosin and analyzed by two pathologists, who observed three millimeter-scale intramucosal DGC foci out of 148 blocks (Fig. 2). Catenin alpha-1 expression was lost in the tumor foci. In patient IV.8, EGD was also normal, but one of 14 random biopsies contained a 1-millimeter intramucosal DGC focus. She subsequently underwent gastrectomy. The pathologist did not identify any additional foci in the surgical specimen.

Catenin alpha-1 expression was normal (>50% of tumor cells) in eighteen *CDH1/CTNNA1*-negative probands from this retrospective series and for whom DGC biopsies or therapeutic gastrectomy specimens were available (fig. 3).

Discussion

Data regarding *CTNNA1* presymptomatic testing are scarce, and nonexistent regarding asymptomatic carrier management, making it difficult for cancer geneticists to inform families. While Weren *et al.* identified the familial mutation in the unaffected mother and daughter of a *CTNNA1* proband, the implications of these findings and subsequent management of the patients are unknown. In this

article, we report in detail and for the first time the clinical consequences of a familial *CTNNA1* mutation in two asymptomatic carriers. Despite having a normal EGD and no sign of cancer in multiple random biopsies, the first carrier followed the recommendations of a multidisciplinary team and had a PTG. Three intramucosal DGC foci were observed. The second carrier had a gastrectomy following the identification of an intramucosal focus by EGD.

HDGC is unique in that asymptomatic *CDH1* mutation carriers are advised to undergo PTG [2], and our observations suggest that the same recommendation should be made to *CTNNA1* mutation carriers.

It is now five years since the first HDGC family carrying a *CTNNA1* germline mutation was reported [8]. Since then, four additional families have been reported [3], [9], firmly establishing *CTNNA1* as a second DGC susceptibility gene in addition to *CDH1*. In the *CTNNA1*-DGC papers, the authors reported only five mutations in a total of 320 *CDH1*-negative probands, using either exome sequencing or a candidate gene approach [3], [8]–[10]. In our study, only 1/41 probands carried a *CTNNA1* mutation, confirming that the gene only accounts for a small proportion of familial DGC or DGC at a young age. Most of the genetic susceptibility therefore remains unaccounted for.

In our study, catenin alpha-1 expression loss in DGC was strongly predictive of a *CTNNA1* germline mutation. Indeed, expression was lost or only observed in a minority of cells (10%) in three mutation carriers from the *CTNNA1* family, while it was retained in eighteen wild-type probands. Our observations confirm, in a large number of cases, observations previously made by Majewski [8]. We thus recommend that immunohistochemistry be performed routinely in all patients with suspected HDGC, as absent or weak expression of catenin alpha-1 suggests genetic susceptibility associated with *CTNNA1*. Intriguingly, over 50% of early diffuse gastric cancers in a Korean study had reduced or absent catenin alpha-1 expression [11]. Expression loss was likely due to purely somatic gene inactivation (tumoral mutations, epigenetic changes), as shown in invasive lobular carcinoma of the breast, considering the rarity of *CTNNA1* germline mutations [12]. The high proportion of DGC losing

catenin alpha-1 expression in the Korean paper contrasts with our observations, and these discrepancies warrant further exploration in future studies. There are no data to suggest that *CDH1* germline or somatic events affect catenin alpha-1 expression.

The latest guidelines clearly state that PTG is recommended in asymptomatic *CDH1* mutation carriers, regardless of EGD findings [2]. The ultimate objective would be to dispense with PTG in a subset of *CDH1* and *CTNNA1* cases, without putting their lives at risk. That would however require a reliable screening tool. In contrast to previous reports, a recent study suggests that EGD, when performed by experts and according to the Cambridge protocol, has good negative predictive value [13]. Indeed it seems to identify large DGC foci at risk of progression to invasive cancer (>3 mm), thus advising which patients should undergo PTG. Smaller foci, whether there are caught or not by multiple random biopsies may however remain quiescent for long periods. Admittedly, we cannot be sure that the small DGC foci observed in our two *CTNNA1* asymptomatic mutation carriers would have progressed into invasive cancers, but it seemed appropriate to follow the *CDH1* guidelines and offer them risk-reducing surgery. Long-term follow up of carriers undergoing regular screening EGD, as well as studies in large cohorts, are needed. Should these findings be confirmed [13], the family reported here, like all families carrying *CDH1* and *CTNNA1* mutations, will be relieved to know that at least a subset of their relatives carrying the mutation will be spared the life-changing PTG procedure in the future.

Author contributions

Manuscript writing: PRB, CC, MS and FC. Data collection: PRB, CC, EG, HD, MW, FC. Patient management (clinical): PRB, CC, HD, MW, JB, JN, YP, AM, VC, IC. Genetic analyses: EG, ME, MZ, FS, JD, FC. Pathology: AC, AMG, MS. Final draft approval: all authors.

Acknowledgments

We are grateful to the following colleagues whose patients were included in this study: Sylviane Olschwang, Pierre Laurent-Puig, Nadem Soufir and Emmanuelle Barouk-Simonet. We also thank

Véronique Byrde for logistical assistance. The pedigree was drawn using Invitae's Family History Tool: <https://www.invitae.com/en/familyhistory/>.

Conflicts of Interest

The authors have no conflict of interest to declare.

Ethical Standards

Retrospective results on a case series are reported in this manuscript. All patients benefited from in-person genetic counseling by a physician with expertise in clinical cancer genetics. They then signed an informed consent form clearly stating that gastric cancer susceptibility genes would be analyzed. Work was done in accordance with French law and National guidelines edited by Health Authorities.

Figure legends

Figure 1. A: Pedigree of the family with the c.2023C>T, p.Gln675* *CTNNA1* pathogenic variant. B. Sanger sequencing, proband's germline DNA. C. Sanger sequencing of tumor tissue from individual III.3.

Figure 2. A and C: Two signet ring cell foci identified in the lamina propria of the prophylactic total gastrectomy specimen (haematoxylin and eosin staining). B and D: Immunohistochemistry. Catenin alpha-1 expression is lost in both tumor foci, while normal tissue shows expression of the protein.

Figure 3. Diffuse gastric cancer in a patient who does not carry a *CTNNA1* germline mutation. Catenin alpha-1 expression is retained in both normal and tumor cells.



REFERENCES

- [1] R. C. Fitzgerald *et al.*, "Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.," *J. Med. Genet.*, vol. 47, no. 7, pp. 436–44, Jul. 2010.
- [2] R. S. van der Post *et al.*, "Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.," *J. Med. Genet.*, vol. 52, no. 6, pp. 361–74, Jun. 2015.
- [3] S. Hansford *et al.*, "Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.," *JAMA Oncol.*, vol. 1, no. 1, pp. 23–32, Apr. 2015.
- [4] P. R. Benusiglio *et al.*, "Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation," *J. Med. Genet.*, vol. 52, no. 8, pp. 563–565, Aug. 2015.
- [5] R. S. van der Post *et al.*, "Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1," *Gastroenterology*, vol. 149, no. 4, p. 897–906.e19, Oct. 2015.
- [6] W. M. Rogers *et al.*, "Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.," *Am. J. Surg. Pathol.*, vol. 32, no. 6, pp. 799–809, Jun. 2008.
- [7] R. Hüneburg *et al.*, "Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients," *Endosc. Int. Open*, vol. 04, no. 12, pp. E1305–E1310, Aug. 2016.
- [8] I. J. Majewski *et al.*, "An α -E-catenin (*CTNNA1*) mutation in hereditary diffuse gastric cancer," *J. Pathol.*, vol. 229, no. 4, pp. 621–629, Mar. 2013.
- [9] R. D. A. Weren *et al.*, "Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility," *J. Med. Genet.*, vol. 55, no. 10, pp. 669–674, Jan. 2018.
- [10] I. P. Vogelaar *et al.*, "Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing," *Eur. J. Hum. Genet.*, vol. 25, no. 11, pp. 1246–1252, Nov. 2017.
- [11] S. Y. Song, S. Kim, D. S. Kim, H. J. Son, J. C. Rhee, and Y. Il Kim, "Abnormal expression of E-


cadherin in early gastric carcinoma: its relationship with macroscopic growth patterns and catenin alpha and beta.," *J. Clin. Gastroenterol.*, vol. 38, no. 3, pp. 252–9, Mar. 2004.

[12] J. S. de Groot *et al.*, "αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer," *J. Pathol.*, vol. 245, no. 4, pp. 456–467, Aug. 2018.

[13] E. Z. Mi *et al.*, "Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status," *Gastrointest. Endosc.*, vol. 87, no. 2, pp. 408–418, Feb. 2018.

A**B****Proband**

c.2023C>T; p.Gln675*

C**III.3**

c.2023C>T; p.Gln675*

